TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1290634
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium pamidronate (APD) administered as a single i.v. infusion of 30, 60 or 90 mg depending on serum calcium.
Study: 1290634
Drug: Mithramycin given
Normalized name: Mithramycine
DrugBank: Plicamycin (DB06810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mithramycin given in doses of 1.25 mg, repeated if necessary within the first three days.
Study: 3937509
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg tablets, 1 tablet twice daily)
Study: 3937509
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg tablets, 1 tablet every morning)
Study: 30785667
Drug: Laxative bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative bowel preparation (LBP)
Study: 30045006
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg in the morning and 5 mg at bedtime for 12 months)
Study: 30045006
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 x 1 tablet for 12 months)
Study: 22585767
Drug: suma/nap 10/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: suma/nap 10/60 mg
Study: 22585767
Drug: suma/nap 30/180
Approvals — FDA: no, EMA: no, PMDA: no
Description: suma/nap 30/180 mg
Study: 22585767
Drug: suma/nap 85/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: suma/nap 85/500 mg
Study: 19892351
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat diet plus 40 mg/day of pravastatin
Study: 10512282
Drug: Ropivacaine (286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (286 mg, 66 mL)
Study: 10512282
Drug: Saline (66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (66 mL)
Study: 2177648
Drug: Dydrogesterone 20
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 20 mg/day for 12 days each calendar month for 3 months, then 10 mg/day for a further 3 months
Study: 2177648
Drug: Dydrogesterone 10
Normalized name: dydrogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg/day in reverse sequence
Study: 2177648
Drug: Both dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both dydrogesterone doses
Study: 375858
Drug: 10-mg troche,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg troche, five times a day for two weeks
Study: 375858
Drug: 50-mg troche,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg troche, five times a day for two weeks
Study: 30593775
Drug: CsA CE
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA CE 0.1% (1 mg/ml) eye drops 4 times daily (high dose)
Study: 30593775
Drug: CsA CE
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA CE twice daily (low dose) plus vehicle twice daily
Study: 30593775
Drug: Vehicle 4
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 4 times daily
Study: 30593775
Drug: High-dose CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CsA CE
Study: 30593775
Drug: Low-dose CsA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CsA CE
Study: 16167722
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (250 mcg every four hours)
Study: 10708161
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.15 mg rhGH/kg/day)
Study: 9210530
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition alone
Study: 9396090
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate ointment (2%)
Study: 9396090
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid ointment (10%)
Study: 8135384
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional medication (BG)
Study: 2680795
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 240 mg twice daily
Study: 797554
Drug: Desonide cream
Normalized name: Desonide Cream
DrugBank: Desonide sodium phosphate (DB15835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desonide cream
Study: 797547
Drug: Fluocinonide cream
Normalized name: Fluocinonide Cream
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide cream
Study: 31053405
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2) and Doxorubicin (45 mg/m2)
Study: 31053405
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2), Doxorubicin (45 mg/m2), and Paclitaxel (160 mg/m2)
Study: 27931762
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 1 mg/kg
Study: 25080875
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (combining pharmacological treatment, education, physical therapy, and cognitive behavioural therapy)
Study: 22899402
Drug: Conventional pharmacologic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacologic treatment
Study: 1397477
Drug: Bezafibrate (BZF)
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (BZF) 400 mg/day for one month
Study: 1397477
Drug: Acipimox (APX)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (APX) 500 mg/day for one month
Study: 3554901
Drug: Nitrazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (10 mg nocte)
Study: 3554901
Drug: Temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (20 mg nocte)
Study: 30154027
Drug: MONEO platform
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: MONEO platform (smartphone-based), cognitive training twice a week, assessed monthly via teleconference
Study: 29864505
Drug: Inorganic NO3-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic NO3- supplementation (beetroot powder; 250 mg of NO3- and 20 mg of NO2-) for four weeks
Study: 24769563
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oils in ethanolic solution mouthrinse
Study: 23232161
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) training combined with Conventional Therapy (CT)
Study: 15840746
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (150 mg for 5 days from the third day of a progesterone withdrawal bleeding)
Study: 12477504
Drug: IV albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV albumin treatment for OHSS
Study: 12477504
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with OHSS before treatment
Study: 9790269
Drug: TAP-144SR (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144SR (long-acting gonadotropin-releasing hormone analog)
Study: 28731609
Drug: Dietary sodium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary sodium intake (mean Na intake: 4309.6 ± 1344.4 mg/day)
Study: 19627212
Drug: Honey solution
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey solution (75 g once daily for 14 days)
Study: 19627212
Drug: Sugar solution
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar solution (honey-comparable, 75 g once daily for 14 days)
Study: 9632446
Drug: Hyperfractionated irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated irradiation plus concurrent chemotherapy (combined treatment)
Study: 8148291
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine sulfate 0.25 mg and fentanyl 25 micrograms via CSE technique
Study: 20886729
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of immunomodulators
Study: 15905656
Drug: Computer-aided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided dosing of warfarin (n=14)
Study: 15905656
Drug: Clinician dosing
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician dosing of warfarin (n=16)
Study: 9178167
Drug: Riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 100 mg daily
Study: 10741628
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day oral mibefradil for 8 days
Study: 10741628
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day oral mibefradil for 8 days
Study: 21640574
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg
Study: 1353717
Drug: salbutamol 5
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 5 mg
Study: 1353717
Drug: fenoterol 5
Normalized name: fenoterol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 5 mg
Study: 8885761
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution
Study: 6342295
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with procaine hydrochloride (control)
Study: 31771512
Drug: Deep cervical
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep cervical block (DCB) receiving 20 mL ropivacaine 0.5% (n=10)
Study: 31771512
Drug: Intermediate cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate cervical block (ICB) receiving 20 mL ropivacaine 0.5% (n=10)
Study: 31771512
Drug: Perivascular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perivascular infiltration of the internal carotid artery (PVB) receiving 20 mL ropivacaine 0.5% and 10 mL ropivacaine 0.3% (n=10)
Study: 26362785
Drug: Preoperative decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative decolonization treatment for S aureus carriers
Study: 26362785
Drug: Noncarriers (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncarriers (no treatment)
Study: 25495568
Drug: Furosemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide and standard-dosed Solifenacin (10 mg per day)
Study: 25495568
Drug: Furosemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide and low-dosed Solifenacin (5 mg per day)
Study: 22521671
Drug: Preoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative ibuprofen (600 mg p.o. 1h before surgery)
Study: 22521671
Drug: Postoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative ibuprofen (placebo after surgery)
Study: 17695436
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CF: cisplatin and 5-fluorouracil)
Study: 16121218
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen including mitoxantrone plus cytarabine, two consolidation courses, one with timed-sequential high-dose cytarabine, asparaginase and amsacrine.
Study: 16121218
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (MT-).
Study: 16121218
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (MT).
Study: 10100788
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy (CEA) with best medical therapy
Study: 7785280
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Volon A
Study: 7785280
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Volon A
Study: 2272190
Drug: Controlled-release trazodone
Normalized name: trazodone hydrochloride Extended Release Oral Tablet [Molipaxin CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release trazodone (150 mg)
Study: 2272190
Drug: Standard trazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trazodone (150 mg)
Study: 12653747
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 20% 5-aminolaevulinic acid (ALA) applied 4 hours before illumination with 100 J cm‐2 narrowband red light (630 +/- 15 nm)
Study: 12653747
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (5-FU) applied to lesions for 4 weeks, with a repeat treatment cycle after 6 weeks if required
Study: 11053909
Drug: Levofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (100 mg t.d.s. orally for 5 days)
Study: 11053909
Drug: Cefazolin sodium
Normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin sodium (1 g b.i.d. intravenously for 5 days)
Study: 9198569
Drug: Tension-free surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension-free surgical treatment
Study: 3455938
Drug: 0.2% CH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CH gel
Study: 3455938
Drug: 0.2% CH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CH solution
Study: 25045152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein provided as a genistein tablet
Study: 25045152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein provided as a genistein tablet in low fat milk
Study: 25045152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein provided as soy milk containing genistein glycosides
Study: 22533447
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus methotrexate (7·5‐15 mg weekly)
Study: 18401809
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) at 30 Hz and 4 mm amplitude for 60 seconds, repeated twice
Study: 16091231
Drug: New antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiretroviral drugs used carefully with an active background regimen
Study: 16091231
Drug: Resistance testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance testing and drug level monitoring
Study: 16091231
Drug: Multiple-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-drug regimens
Study: 11690728
Drug: Pregabalin (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (exact dosage not specified)
Study: 27598553
Drug: Proprioceptive/strengthening exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive/strengthening exercises combined with manual therapy (mobilizations to influence joint and nerve structures)
Study: 23538020
Drug: Ezetimibe added
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe added to maximum tolerated statin therapy
Study: 23538020
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated statin therapy without ezetimibe
Study: 20655105
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg per day
Study: 18211506
Drug: Steroid-free group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free group (n = 112)
Study: 18211506
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal group (n = 115)
Study: 18211506
Drug: Standard steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroids group (n = 109)
Study: 16984076
Drug: Multiple-family group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-family group treatment (MFGT)
Study: 10920067
Drug: Carvedilol (49±18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (49±18 mg/d)
Study: 10920067
Drug: Metoprolol (124±55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (124±55 mg/d)
Study: 1551312
Drug: Intravenous metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metformin infusion
Study: 6485438
Drug: NaCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl infusion (control)
Study: 30113051
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (8 × 10^9 CFU day‐1) for 12 weeks
Study: 24668063
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (RadiaPlexRx™ ointment) applied topically three times a day until 1 month postradiation
Study: 19945545
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone supplementation in brain stem death setting
Study: 12633121
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 0.95 mg/day)
Study: 3912960
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg/day
Study: 7460480
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg three times a day)
Study: 31237644
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month of DAPT followed by clopidogrel monotherapy
Study: 31237644
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of DAPT with aspirin and clopidogrel
Study: 29228964
Drug: Probiotics (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2.5 × 10^9 cfu/g) containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)
Study: 26387049
Drug: Alcohol-Adapted Anger
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-Adapted Anger Management Treatment (AM)
Study: 26387049
Drug: Alcoholics Anonymous
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholics Anonymous Facilitation treatment (AAF)
Study: 16739840
Drug: Needle-knife therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife therapy
Study: 15010365
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg/d)
Study: 10918156
Drug: Microwave coagulation
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave coagulation therapy (14 patients)
Study: 10918156
Drug: Microwave coagulation
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave coagulation therapy
Study: 8791968
Drug: Cimetidine >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine > or = 2 g daily
Study: 8791968
Drug: Cimetidine (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (general treatment)
Study: 28434547
Drug: Stress-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress-dose corticosteroid (SDC) regimen
Study: 31284871
Drug: Intravenous Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketamine (0.3 mg/kg)
Study: 31284871
Drug: Intravenous Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Morphine (0.1 mg/kg)
Study: 19863578
Drug: Carisbamate 400
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 400 mg/day
Study: 10505300
Drug: Cerivastatin 0.05‐0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.05‐0.8 mg orally, given as single or multiple once‐daily doses
Study: 10505300
Drug: Cerivastatin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin administered at different times (morning, evening meal, bedtime)
Study: 10505300
Drug: Marketed tablet
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed tablet strengths and drug formulations from different sources
Study: 8605793
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 0.1 mg/kg (n = 3)
Study: 8605793
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 0.33 mg/kg (n = 3)
Study: 8605793
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 1.0 mg/kg (n = 3)
Study: 8605793
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787